GIANAKAKOS ANASTASIOS

SEC source: 0001193125-26-277916 · ownership.xml · derivative · entry 9

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 0

Underlying: Common Stock · 498,692 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001193125-26-277916 · ownership.xml · derivative · entry 8

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By KCM 2023 Trust

Disclosed balance after: 0

Underlying: Common Stock · 41,001 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F3 · ownership.nature: Represents shares held by KCM 2023 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001193125-26-277916 · ownership.xml · derivative · entry 7

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By AEG 2021 Trust

Disclosed balance after: 0

Underlying: Common Stock · 28,702 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: Represents shares held by AEG 2021 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001193125-26-277916 · ownership.xml · nonDerivative · entry 3

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By spouse

Disclosed balance after: 498,692

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F4 · ownership.nature: The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001193125-26-277916 · ownership.xml · nonDerivative · entry 2

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By KCM 2023 Trust

Disclosed balance after: 2,422,520

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F3 · ownership.nature: Represents shares held by KCM 2023 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001193125-26-277916 · ownership.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By AEG 2021 Trust

Disclosed balance after: 5,665,090

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series A Preferred Stock and Series B Preferred Stock (together the "Preferred Stock") was convertible into Common Stock on a 1.5928 for 1 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 upon the effectiveness of the Issuer's registration statement on Form S-1 relating to its initial public offering on June 17, 2026 and without payment of consideration. The Preferred Stock had no expiration date.

F2 · ownership.nature: Represents shares held by AEG 2021 Trust. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001831283-24-000011 · wk-form4_1708463476.xml · derivative · entry 4

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 36,300 shares

Expires 2032-06-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares underlying the option became exercisable in full on June 23, 2023.

SEC source: 0001831283-24-000011 · wk-form4_1708463476.xml · nonDerivative · entry 2

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,630

SEC source: 0001831283-24-000011 · wk-form4_1708463476.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,848

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001831283-23-000094 · wk-form4_1687551713.xml · derivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,300

Underlying: Ordinary Shares · 36,300 shares

Expires 2033-06-21

F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

SEC source: 0001831283-22-000050 · wf-form4_165636106038470.xml · derivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,300

Underlying: Ordinary Shares · 36,300 shares

Expires 2032-06-23

F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.

SEC source: 0000899243-22-000135 · doc4.xml · derivative · entry 3

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,647

Underlying: Ordinary Shares · 36,548 shares

Expires 2030-12-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares underlying the option vested and became exercisable on the first anniversary of the commencement date, December 17, 2021; the remainder shall vest and become exercisable in 3 equal annual installments such that the option shall be fully vested on December 17, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date.

SEC source: 0000899243-22-000135 · doc4.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,548

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-20-031746 · doc4.xml · derivative · entry 14

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 142,733 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

SEC source: 0000899243-20-031746 · doc4.xml · derivative · entry 13

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 236,500 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

SEC source: 0000899243-20-031746 · doc4.xml · derivative · entry 12

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 184,100 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

SEC source: 0000899243-20-031746 · doc4.xml · derivative · entry 11

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 303,500 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

SEC source: 0000899243-20-031746 · doc4.xml · derivative · entry 10

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 72,562 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

SEC source: 0000899243-20-031746 · doc4.xml · derivative · entry 9

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 149,517 shares

Expires not disclosed

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

SEC source: 0000899243-20-031746 · doc4.xml · nonDerivative · entry 8

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust 3

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

SEC source: 0000899243-20-031746 · doc4.xml · nonDerivative · entry 7

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust 2

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

SEC source: 0000899243-20-031746 · doc4.xml · nonDerivative · entry 6

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust 1

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

SEC source: 0000899243-20-031746 · doc4.xml · nonDerivative · entry 5

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By reporting Person's Trust 6

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

SEC source: 0000899243-20-031746 · doc4.xml · nonDerivative · entry 4

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Reporting Person's Trust 5

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

SEC source: 0000899243-20-031746 · doc4.xml · nonDerivative · entry 3

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Reporting Person's Trust 4

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

SEC source: 0000899243-20-031746 · doc4.xml · nonDerivative · entry 2

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Reporting Person's Trust 2

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

SEC source: 0000899243-20-031746 · doc4.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

SEC source: 0000950123-20-006771 · doc4.xml · nonDerivative · entry 2

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,122

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019.

F3 · price: Represents the weighted average price of the shares sold ranging from $94.01 to $94.75 per share.

SEC source: 0000950123-20-006771 · doc4.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,346

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $92.98 to $93.93 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.

SEC source: 0000899243-20-015250 · doc4.xml · nonDerivative · entry 5

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,122

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019.

F6 · price: Represents the weighted average sale price of the shares sold ranging from $104.33 to $105.06 per share.

SEC source: 0000899243-20-015250 · doc4.xml · nonDerivative · entry 4

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,441

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019.

F5 · price: Represents the weighted average sale price of the shares sold ranging from $103.30 to $104.10 per share.

SEC source: 0000899243-20-015250 · doc4.xml · nonDerivative · entry 3

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,326

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019.

F4 · price: Represents the weighted average sale price of the shares sold ranging from $102.30 to $103.04 per share.

SEC source: 0000899243-20-015250 · doc4.xml · nonDerivative · entry 2

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,722

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019.

F3 · price: Represents the weighted average sale price of the shares sold ranging from $101.28 to $102.17 per share.

SEC source: 0000899243-20-015250 · doc4.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,522

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 3, 2019.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $100.27 to $101.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in footnotes 2, 3, 4, 5, and 6.

SEC source: 0000899243-20-013695 · doc4.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,122

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

SEC source: 0000899243-20-013004 · doc4.xml · nonDerivative · entry 5

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,122

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F7 · price: Represents the weighted average price of the shares sold ranging from $103.19 to $103.54 per share.

SEC source: 0000899243-20-013004 · doc4.xml · nonDerivative · entry 4

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,722

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: Represents the weighted average price of the shares sold ranging from $102.11 to $103.09 per share.

SEC source: 0000899243-20-013004 · doc4.xml · nonDerivative · entry 3

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,241

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: Represents the weighted average price of the shares sold ranging from $101.07 to $102.05 per share.

SEC source: 0000899243-20-013004 · doc4.xml · nonDerivative · entry 2

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,822

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: Represents the weighted average price of the shares sold ranging from $100.01 to $100.94 per share.

SEC source: 0000899243-20-013004 · doc4.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,522

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $98.50 to $99.46 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in this footnote and footnotes 4 through 7.

F3 · balance_after: Excludes 10,000 shares previously owned directly which were contributed on May 6, 2020 to the MJA Legacy Trust, of which the Reporting Person's children are beneficiaries.

SEC source: 0000899243-20-012163 · doc4.xml · nonDerivative · entry 4

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,122

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: Represents the weighted average price of the shares sold ranging from $59.67 to $60.17 per share.

SEC source: 0000899243-20-012163 · doc4.xml · nonDerivative · entry 3

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,427

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: Represents the weighted average price of the shares sold ranging from $58.60 to $59.45 per share.

SEC source: 0000899243-20-012163 · doc4.xml · nonDerivative · entry 2

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,336

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: Represents the weighted average price of the shares sold ranging from $57.48 to $58.40 per share.

SEC source: 0000899243-20-012163 · doc4.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,736

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: Represents the weighted average sale price of the shares sold ranging from $56.46 to $57.35 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges reported in footnotes 2, 4, 5 and 6.

F3 · balance_after: Includes 95,540 shares previously held by The TKG Trust dated November 2, 2006 which were contributed to the Reporting Person directly on May 1, 2020, and excludes (a) 300,000 shares previously owned directly which were contributed to The Tassos Gianakakos 2020 Annuity Trust on May 1, 2020 and (b) 6,000 shares previously owned directly which were contributed to The TKG 2020 Irrevocable Trust on May 1, 2020.

SEC source: 0000899243-20-011908 · doc4.xml · derivative · entry 7

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,626

Underlying: Common Stock · 11,500 shares

Expires 2025-06-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on June 4, 2016, and the remaining shares subject to this option vest and become exercisable in monthly installments through June 4, 2019, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

SEC source: 0000899243-20-011908 · doc4.xml · nonDerivative · entry 2

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 289,582

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-20-011908 · doc4.xml · nonDerivative · entry 1

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,082

F1 · kind: Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c).

SEC source: 0000899243-20-011019 · doc4.xml · nonDerivative · entry 4

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Reporting Person's Trust 3

Disclosed balance after: 0

SEC source: 0000899243-20-011019 · doc4.xml · nonDerivative · entry 3

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277,661

SEC source: 0000899243-20-011019 · doc4.xml · nonDerivative · entry 2

GIANAKAKOS ANASTASIOS · CIK 0001413822 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Reporting Person's Trust 3

Disclosed balance after: 122,661